Azka Ali, MD (@AzkaAliMD) profile picture

Azka Ali, MD

@AzkaAliMD

Breast Medical Oncologist @clevelandclinic Taussig Can Inst. | Interested in experimental therapeutics #bcsm | @hemeoncgators and @MUSC_COM alum. Views = me

 Cleveland, OH
my.clevelandclinic.org/staff/30132-azka-ali
Joined March 2013
  • Tweets185
  • Following197
  • Followers363
6Media
Photo by Azka Ali, MD (@AzkaAliMD)Photo by Azka Ali, MD (@AzkaAliMD)Photo by Azka Ali, MD (@AzkaAliMD)Photo by Azka Ali, MD (@AzkaAliMD)Photo by Azka Ali, MD (@AzkaAliMD)Photo by Azka Ali, MD (@AzkaAliMD)
Use of Vaginal Estrogen in Breast and Gynecologic Cancer Survivors. Co-authored by @AzkaAliMD. Read the full article. bit.ly/4rSrcCx #BreastCancer #bcsm #gyncsm
Use of Vaginal Estrogen in Breast and Gynecologic Cancer Survivors | JCO Oncology Practice

Use of Vaginal Estrogen in Breast and Gynecologic Cancer Survivors | JCO Oncology Practice

To review the safety, efficacy, and clinical considerations of vaginal estrogen therapy for the treatment of genitourinary syndrome of menopause (GSM) in patients with a history of breast or gyneco...

ascopubs.org
1
1
420
Azka Ali, MD retweeted
Yakup Ergün (@dr_yakupergun) profile picture
Yakup Ergün
@dr_yakupergunOct 6
Use of Vaginal Estrogen in Breast and Gynecologic Cancer Survivors Great review👇 ascopubs.org/doi/10.1200/OP-…
Image from Yakup Ergün (@dr_yakupergun)
14
1
34
4,982
Use of Vaginal Estrogen in Breast and Gynecologic Cancer Survivors | JCO Oncology Practice ascopubs.org/doi/10.1200/OP-… @OncoAlert @JCOOP_ASCO @MMAlHilli @ClevelandClinic in selected patients with refractory symptoms low dose vaginal estrogen could be effective !
Image from Jame Abraham, MD, FACP (@jamecancerdoc)
Image from Jame Abraham, MD, FACP (@jamecancerdoc)
3
37
76
5,777
Biology continues to be more complicated than stage.
JNCI (@JNCI_Now) profile pictureJNCI@JNCI_NowJul 31
🔵Real-world HR+/HER2− early #BreastCancer (Flatiron EHR, n=7,481; 78-mo FU). N0 with high-risk features had recurrence & mortality risk comparable to N1, indicating meaningful risk beyond nodal status. 🖋️@PTarantinoMD @DrSGraff 🔗 oxford.ly/4vMKrgV
Recurrence risk in HR-positive/HER2-negative early breast cancer: real-world US electronic health...

Recurrence risk in HR-positive/HER2-negative early breast cancer: real-world US electronic health...

AbstractBackground. The NATALEE and monarchE trials showed statistically significant invasive disease-free survival benefits with the addition of a cyclin-

academic.oup.com
1
8
30
5,816
Check out our @JACCJournals editorial (jacc.org/doi/10.1016/j.jacc.…) on the FOURIER Prespecified Analysis showing obesity-associated benefit from PCSK9i, evolocumab (jacc.org/doi/10.1016/j.jacc.…). @CBallantyneMD @arsalanhamid93 @vijay_nambi @hwubcm
Reducing Cardiovascular Disease Risk in Obesity: An Unexpected But Welcome FOURIER Transformation

Reducing Cardiovascular Disease Risk in Obesity: An Unexpected But Welcome FOURIER Transformation

jacc.org
3
1
9
2,117
It is a beautiful day in #cleveland ⁦@bikeVeloSano⁩ ⁦@ClevelandClinic⁩ !
Image from Jame Abraham, MD, FACP (@jamecancerdoc)
Image from Jame Abraham, MD, FACP (@jamecancerdoc)
Image from Jame Abraham, MD, FACP (@jamecancerdoc)
4
15
1,179
Thanks @ZunairahShah for moderating a wonderful session
Zunairah Shah (@ZunairahShah) profile pictureZunairah Shah@ZunairahShah6 Sep 2025
Amazing educational webinar by Dr. Ali @AzkaAliMD on ADCs in HR+ MBC with evidence, nuance, and real-world tips.
Image from Zunairah Shah (@ZunairahShah)
2
15
2,418
Azka Ali, MD retweeted
DAVA Oncology (@DAVAOnc) profile picture
DAVA Oncology
@DAVAOnc21 Aug 2025
Dr. @AzkaAliMD (@ClevelandClinic) shares how CNN-based AI models (e.g., IbRiS) applied to H&E slides predict DFS/OS in ER+ breast cancer; retrospectively validated across U.S. & India cohorts. Outperforms Oncotype in ILC & Black pts. Scalable, low-cost risk tool. #DAVABreast
Image from DAVA Oncology (@DAVAOnc)
Image from DAVA Oncology (@DAVAOnc)
Image from DAVA Oncology (@DAVAOnc)
Image from DAVA Oncology (@DAVAOnc)
2
1
5
730
Azka Ali, MD retweeted
DAVA Oncology (@DAVAOnc) profile picture
DAVA Oncology
@DAVAOnc20 Aug 2025
USP1 regulates replication fork stability. Dr. @AzkaAliMD (@ClevelandClinic) highlights KSQi (RO7623066) as a USP1i that synergizes with Olaparib. Tumor regressions seen in BRCA1+ mBC; PK and biomarker data support continued study. #DAVABreast
Image from DAVA Oncology (@DAVAOnc)
Image from DAVA Oncology (@DAVAOnc)
Image from DAVA Oncology (@DAVAOnc)
Image from DAVA Oncology (@DAVAOnc)
1
5
366
Dr. Shreya Sengupta was a gifted clinician, rising health services researcher, and fierce advocate for the most vulnerable. Her work transformed ALD care and advanced equity in hepatology. Thank you @AASLDtweets for honoring her legacy. Donate: aasld.org/shreya-sengupta-md
Shreya Sengupta, MD

Shreya Sengupta, MD

A Tribute to AASLD Member Shreya Sengupta, MD

aasld.org
2
9
2
28
7,702
It's been exactly 20 years since my first day of internship As I reflect on my disproportionate aging since then (gray hairs >>> wisdom), here are my 10 unsolicited recommendations for any colleague embarking on residency THE "ATTENDING ADVICE YOU DIDN'T ASK FOR" THREAD ...
18
65
9
382
62,840
9th Annual Cleveland Breast Cancer Summit: Collaborating for a Cure- Friday August 8, 2025. Triple Negative Breast Cancer clevelandclinicmeded.com/liv…
Image from Stephanie Valente (@DrStephValente)
6
19
1,468
Slideshow: ADCs like #DatoDXd and next-gen endocrine therapies offer new options—but with more choice comes tougher clinical questions. bit.ly/3Z5qBjM #BreastCancer #Oncology #ADCs #EndocrineTherapy @jhaveri_komal @ErinCobain @AzkaAliMD @dradityabardia @jrgralow
1
1
173
This!
Harold J. Burstein, MD, PhD, FASCO (@DrHBurstein) profile pictureHarold J. Burstein, MD, PhD, FASCO
@DrHBurstein23 May 2025
Replying to @DrHBurstein
That's the world's literature on ivermectin in advanced cancer. 8 pts with TNBC getting ICI + ivermectin, 1 response (same rate as ICI alone, in other trials), avg PFS of 2.5 m. So, at present, there is no evidence for meaningful clinical activity of ivermectin in cancer.
3
327
Honored to accept the Velosano Pilot Award investigating the role of ctDNA in metastatic lobular breast cancer. Thanks to @MeganKruseMD and @StoverLab for their support! @bikeVeloSano @ClevelandClinic @CleClinicMD
3
1
33
1,630
So well deserving! Congrats @gt_budd! Amazing colleague, mentor, and friend! @ClevelandClinic @CleClinicMD
Jame Abraham, MD, FACP (@jamecancerdoc) profile pictureJame Abraham, MD, FACP@jamecancerdoc6 Feb 2025
Please join me in congratulating @gt_budd for receiving the Legacy Coin from @TomMihaljevicMD the President and CEO of @ClevelandClinic ! Dr. Budd embodies the very essence of a @CleClinicMD !!
Image from Jame Abraham, MD, FACP (@jamecancerdoc)
Image from Jame Abraham, MD, FACP (@jamecancerdoc)
5
331
Wonderful to see @ThejusJay featured in @DFarberYoungCRC ! @ccfhemonc @ClevelandClinic @CleClinicMD Alumni!
Dana-Farber's Young-Onset Colorectal Cancer Center (@DFarberYoungCRC) profile pictureDana-Farber's Young-Onset Colorectal Cancer Center
@DFarberYoungCRC31 Jan 2025
Today’s Specialist Spotlight is @ThejusJay Dr. Jayakrishnan is a Medical Oncologist at DFCI treating patients with all types of GI cancers and focuses his research on critical gaps in the understanding of early-onset GI cancers through translational research. Welcome to the team!
Image from Dana-Farber's Young-Onset Colorectal Cancer Center (@DFarberYoungCRC)
2
1
1
12
1,825
This!
Smitha Krishnamurthi (@smitha42) profile pictureSmitha Krishnamurthi@smitha4223 Jan 2025
#Cancer is the #1 cause of death in people below the age of 85. There is so much work to do. We need to invest more in @NCI, not less.
2
203
KEYNOTE-522: Exploratory #Biomarker analysis highlights TMB & T-cell-inflamed GEP as linked to better outcomes in early-stage #TripleNegativeBreastCancer. #Pembrolizumab shows efficacy across biomarker-defined subgroups. bit.ly/41Vka55 @AzkaAliMD #SABCS24 #TNBC
1
217
Wonderful to see @ClevelandClinic along with other major cancer centers !
LARVOL (@Larvol) profile pictureLARVOL
@Larvol24 Dec 2024
Here are the Top 10 Most Active Cancer Institutes that are leading the conversation in innovation and insights, ranked based on oncologists' reactions and engagement on X (formerly Twitter). #LARVOL #CancerResearch #Oncology #OncologyInsights #CancerData
Image from LARVOL (@Larvol)
1
6
29
2,715
Load more